Patents by Inventor Robert GENTLEMAN

Robert GENTLEMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE
    Publication number: 20220090205
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Application
    Filed: June 1, 2021
    Publication date: March 24, 2022
    Inventors: Christiaan Nicolaas KLIJN, James LEE, David Hugh STOKOE, Robert GENTLEMAN, Florian GNAD, Leonard David GOLDSTEIN, Juliann CHMIELECKI, Ryan J. HARTMAIER
  • Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene
    Patent number: 11066709
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 20, 2021
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: Christiaan Nicolaas Klijn, James Lee, David Hugh Stokoe, Robert Gentleman, Florian Gnad, Leonard David Goldstein, Juliann Chmielecki, Ryan J. Hartmaier
  • METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE
    Publication number: 20190218618
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 18, 2019
    Inventors: Christiaan Nicolaas KLIJN, James LEE, David Hugh STOKOE, Robert GENTLEMAN, Florian GNAD, Leonard David GOLDSTEIN, Juliann CHMIELECKI, Ryan J. HARTMAIER